Nonsteroidal anti-inflammatory drug use is associated with cancer risk reduction in chronic dialysis patients

Kidney International

Volumn 84, Issue 1, 2013, Pages 198-205

  Ou, Shuo Ming ^a   Chen, Yung Tai ^a,b   Chao, Pei Wen ^c   Lee, Yi Jung ^a,d   Liu, Chia Jen ^a,d   Yeh, Chiu Mei ^d   Chen, Tzeng Ji ^d   Chen, Tzen Wen ^e,f   Yang, Wu Chang ^a,d   Li, Szu Yuan ^a,d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FIBRIC ACID DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TICLOPIDINE; WARFARIN;

ADULT; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIALYSIS; DIGESTIVE SYSTEM CANCER; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; KIDNEY CANCER; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; PRIORITY JOURNAL; PROPENSITY SCORE; RESPIRATORY TRACT CANCER; RISK REDUCTION; TAIWAN; UPPER GASTROINTESTINAL BLEEDING;

EID: 84879688027     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.79     Document Type: Article

References (42)

1. Rizzo MT. Cyclooxygenase-2 in oncogenesis. Clin Chim Acta 2011; 412: 671-687.
2. Siemes C, Visser LE, Coebergh JW et al. Protective effect of NSAIDs on cancer and influence of COX-2 C(765G) genotype. Curr Cancer Drug Targets 2008; 8: 753-764.
3. Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved -editorial. Am J Nephrol 1998; 18: 89-95.
4. Lin HF, Li YH, Wang CH et al. Increased risk of cancer in chronic dialysis patients: a population-based cohort study in Taiwan. Nephrol Dial Transplant 2012; 27: 1585-1590.
5. Harris RE, Beebe-Donk J, Doss H et al. Aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005; 13: 559-583.
6. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-266.
7. Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-99.
8. Cuzick J, Otto F, Baron JA et al. Aspirin and non-steroidal antiinflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10: 501-507.
9. Smalley W, Ray WA, Daugherty J et al. Use of nonsteroidal antiinflammatory drugs and incidence of colorectal cancer: a populationbased study. Arch Intern Med 1999; 159: 161-166.
10. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 2000; 51: 511-523.
11. Tsan YT, Lee CH, Wang JD et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012; 30: 623-630.
12. Harris RE, Chlebowski RT, Jackson RD et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003; 63: 6096-6101.
13. Terry MB, Gammon MD, Zhang FF et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004; 291: 2433-2440.
14. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and coloncancer chemoprevention. Lancet Oncol 2002; 3: 166-174.
15. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Eng J Med 2000; 342: 1960-1968.
16. Tsujii M, Kawano S, Tsuji S et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
17. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal antiinflammatory drugs. Adv Pharmacol 1997; 39: 1-20.
18. Brueggemeier RW, Diaz-Cruz ES, Li PK et al. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol 2005; 95: 129-136.
19. Ou JH, Pan CC, Lin JS et al. Transitional cell carcinoma in dialysis patients. Eur Urol 2000; 37: 90-94.
20. Chang CH, Yang CM, Yang AH. Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan. Cancer 2007; 109: 1487-1492.
21. Stewart JH, Vajdic CM, van Leeuwen MT et al. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 2009; 24: 3225-3231.
22. Lai MN, Wang SM, Chen PC et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Nat Cancer Inst 2010; 102: 179-186.
23. Chen CJ, Hsu LI, Wang CH et al. Biomarkers of exposure, effect, and susceptibility of arsenic-induced health hazards in Taiwan. Toxicol Appl Pharmacol 2005; 206: 198-206.
24. Castelao JE, Yuan JM, Gago-Dominguez M et al. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82: 1364-1369.
25. McCredie M, Ford JM, Taylor JS et al. Analgesics and cancer of the renal pelvis in New South Wales. Cancer 1982; 49: 2617-2625.
26. McCredie M, Stewart JH, Ford JM. Analgesics and tobacco as risk factors for cancer of the ureter and renal pelvis. J Urol 1983; 130: 28-30.
27. Gago-Dominguez M, Yuan JM, Castelao JE et al. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 1999; 81: 542-548.
28. Chow WH, McLaughlin JK, Linet MS et al. Use of analgesics and risk of renal cell cancer. Int J Cancer 1994; 59: 467-470.
29. Hori Y, Oda Y, Kiyoshima K et al. Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis. J Pathol 2007; 212: 218-226.
30. Mellemkjaer L, Blot WJ, Sorensen HT et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol 2002; 53: 173-181.
31. Garcia Rodriguez LA, Gonzalez-Perez A, Bueno H et al. NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PloS One 2011; 6: e16780.
32. Bleumink GS, Feenstra J, Sturkenboom MC et al. Nonsteroidal antiinflammatory drugs and heart failure. Drugs 2003; 63: 525-534.
33. Chang CH, Shau WY, Kuo CW et al. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study. Stroke 2010; 41: 1884-1890.
34. Yao M, Lam EC, Kelly CR et al. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer 2004; 90: 712-719.
35. Kang JH, Song KH, Jeong KC et al. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer 2011; 11: 334.
36. Richardsen E, Uglehus RD, Due J et al. COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67. Cancer Epidemiol 2010; 34: 316-322.
37. Chao PW, Ou SM, Chen YT et al. Acute appendicitis in patients with endstage renal disease. J Gastrointest Surg 2012; 16: 1940-1946.
38. Liu CJ, Chang YS, Teng CJ et al. Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: a nationwide population-based study. Eur J Neurol 2012; 19: 746-751.
39. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127: 1044-1050.
40. WHO Collaborating Center for Drugs Statistics Methodology. ATC Index with DDDs 2003. WHO: Oslo, Norway, 2003.
41. Schuz J, Jacobsen R, Olsen JH et al. Cellular telephone use and cancer risk: update of a nationwide Danish cohort. J Natl Cancer Inst 2006; 98: 1707-1713.
42. Win AK, Young JP, Lindor NM et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012; 30: 958-964.